[AACR] 온라인 바카라 사이트 Reports Enhanced Bioavailability of SC Infliximab with HyDIFFUZE™ in Rats; AACR 2025 Abstract Selected

[by Sung, JaeJun] 온라인 바카라 사이트, a subsidiary of Huons Global,announced on April 3 thatits abstract titled “The Role of HyDIFFUZE™ in Co-formulation with Subcutaneous Infliximab” has been selected for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place on April 28, 2025.

The study demonstrated that HyDIFFUZE™ (rHuPH20) significantly improves the relative bioavailability of co-formulated infliximab compared to infliximab without rHuPH20 when administered subcutaneously.

These findings suggest that co-formulation with HyDIFFUZETM (rHuPH20) may reduce the required dose of infliximab while maintaining equivalent therapeutic efficacy and potentially extending dosing interval in the maintenance regimen.

온라인 바카라 사이트 previously validated the role of HyDIFFUZE™ (rHuPH20) as a locally acting, transient permeation enhancer for subcutaneous delivery of high-dose, high-volume biotherapeutics, supported by dye dispersion studies in nude mice and in vivo comparative pharmacokinetic (PK) studies in Sprague-Dawley rats.

In parallel, 온라인 바카라 사이트 is currently conducting a pivotal Phase 1 clinical trial in South Korea for Hydizyme™, a stand-alone recombinant human hyaluronidase (rHuPH20) drug product, with the goal of obtaining product approval from the Ministry of Food and Drug Safety (MFDS) by 2026.

“온라인 바카라 사이트 is committed to converting high-dose, high-volume antibody-based biotherapeutics from intravenous (IV) infusion to subcutaneous (SC) injection using human hyaluronidase PH20,” said Dr. Young Sun Lee, Chief Business Officer of 온라인 바카라 사이트.

Lee added, “Our HyDIFFUZE™ (rHuPH20) drug delivery technology is redefining the landscape of SC antibody development and expanding patient access to more convenient and effective subcutaneous antibody therapies.”